Differential expression of MART-1 in primary and metastatic melanoma lesions

Journal of Immunotherapy

Volumn 20, Issue 6, 1997, Pages 460-465

  Kageshita, Toshiro ^a   Kawakami, Yutaka ^b   Hirai, Shunji ^a   Ono, Tomomichi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

GP100; MART 1; Melanocytic tumor

Indexed keywords

MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; PIGMENTED NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030785491     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199711000-00005     Document Type: Article

References (28)

1. Kawakami Y, Robbins PF, Wang RF, Rosenberg SA. Identification of tumor-regression antigens in melanoma. In: Devita VT, Heilman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott-Raven, 1996:3-21.
2. Chen YT, Stockert E, Tsang S, Coplan KE, OLd LJ. Immunophe-notyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995;92:8125-9.
3. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
4. Kawakami Y. Cloning of the gene coding for a shared human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-61.
5. Kawakami Y, Eliyasu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
6. Kawakami Y, Battles IK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1997;202:13-25.
7. Marincola FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gplOO in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996;19:192-205.
8. Kageshita T, Nakamura T, Yamada M, Kuriya N, Arao T, Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res 1991;51:1726-32.
9. Hicklin DJ, Kageshita T, Ferrone S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens 1996;48:38-46.
10. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C and -D antigens. Am J Clin Pathol 1978;69:103-20.
11. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, eds. Manual for staging of cancer: American Joint Committee on Cancer. 4th ed. Philadelphia: IB Lippincott, 1992:143-8.
12. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
13. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
14. Chen YT, Stockert E, lungbluth A, et al. Serological analysis of Melan-A(MART-l), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996;93:5915-9.
15. Herlyn M, Koplowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Ann Rev Immunol 1988;6:283-308.
16. Herlyn M, Menrad A, Koplowski H. Structure, function and clinical significance of human tumor antigens. J Natl Cancer Inst 1990;82:1883-9.
17. Weterman MAI, van Muijen GNP, Bloemers HPJ, Ruiter DJ. Biology of disease: molecular markers of melanocytic tumor progression. Lab Invest 1994;70:593-608.
18. Albelda SM, Elder D, Stewart R, Laszlo D, Herlyn M, Clayton B. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 1990;50:569-71.
19. Johnson JP, Stade BG, Holzman B, Schwable W, Riethmuller G. De novo expression of intercellular adhesion molecule-1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 1989;86:641-4.
20. Natali PG, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule-1 expression in primary and metastatic melanoma lesions. Cancer Res 1990;50:1271-8.
21. Kageshita T, Yoshii A, Kimura T, et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res 1993;53:4927-32.
22. Kageshita T, Kuriya N, Ono T, et al. Association of high molecular weight-melanoma associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res 1993;53:2830-3.
23. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Biggotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992;52:197-201.
24. Marincola FM, Venzon D, White D, et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy [published erratum appeared in Cancer Res 1993;53:3846]. Cancer Res 1992;52:6561-6.
25. Kageshita T, Naruse T, Hirai S, et al. HLA class I antigens in Japanese patients with melanoma. J Immunother 1997;19:428-32.
26. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470-6.
27. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
28. Cromme FV, Airey I, Heemels MT, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335-40.